ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Younossian, A. B.
Right arrow Articles by Janssens, J-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Younossian, A. B.
Right arrow Articles by Janssens, J-P.
Eur Respir J 2005; 26:462-464
Copyright ©ERS Journals Ltd 2005

High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis

A. B. Younossian1, T. Rochat1, J-P. Ketterer2, J. Wacker2 and J-P. Janssens1

1 Division of Pulmonary Diseases, Geneva University Hospital, Geneva, and 2 La Chaux-de-Fonds, Neuchâtel, Switzerland.

CORRESPONDENCE: J-P. Janssens, Centre antituberculeux, Hôpital Cantonal Universitaire, 1211 Geneva 14, Switzerland. Fax: 41 223799929. E-mail: Jean-Paul.Janssens@hcuge.ch

Keywords: Ethambutol, hepatotoxicity, latent tuberculous infection, multidrug-resistant tuberculosis, pyrazinamide, treatment

Received: January 16, 2005
Accepted May 31, 2005


   ABSTRACT
TOP
 ABSTRACT
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Pyrazinamide (PZA) combined with either ethambutol (EMB) or a fluoroquinolone for 6–12 months is one of the treatments recommended for latent tuberculosis infection (LTBI) in contacts exposed to multidrug-resistant tuberculosis (MDR-TB). The aim of the present study was to describe the side effects related to combined PZA and EMB treatment given for LTBI, in contacts previously exposed to MDR-TB.

In total, 12 consecutive contacts, all of African origin and aged 38±5 yrs, were treated with daily PZA (23±4 mg·kg–1) and EMB (17±4 mg·kg–1) at Geneva University Hospital outpatient clinic (Switzerland), as a result of contact-tracing procedures for two patients with contagious MDR-TB.

Clinical status and liver function tests (aspartate aminotransferase (ALAT) and alanine aminotransferase (ASAT)) were monitored monthly. In seven cases (58%) treatment was discontinued after a median of 119 days, due to hepatic toxicity in six cases (ALAT or ASAT elevation more than four times the upper normal limit), and gastrointestinal symptoms in one case.

In conclusion, combined pyrazinamide and ethambutol for latent tuberculosis infection may be associated with a high risk of hepatic toxicity, and warrants close monitoring. There is clearly a need for alternative preventive treatments for contacts exposed to multidrug-resistant tuberculosis.

Multidrug-resistant tuberculosis (MDR-TB) is defined as a tuberculous infection by bacilli showing simultaneous resistance to at least isoniazid (INH) and rifampicin (RIF). In Switzerland, between 1999–2000, 1.2% of all declared cases of tuberculosis (TB) were MDR-TB, and all were foreign-born 1. Maintaining a high index of suspicion in patients with risk-factors for MDR-TB, rapid identification (whenever possible through genotyping for resistance to RIF), isolation of active cases, directly observed therapy implementation, and treatment of latent tuberculosis infection (LTBI) caused by exposure to cases of MDR-TB are all essential to control the spread of resistant bacilli. The current USA guidelines recommend the use of pyrazinamide (PZA) and either ethambutol (EMB) or a fluoroquinolone as a first-line treatment (before results of susceptibility testing for infecting strain are available) for adults with LTBI related to MDR-TB, for 6–12 months 2. These recommendations are supported by expert opinion, but not by controlled trials 3.

Recent reports have highlighted the potential hepatotoxicity of combined treatment with RIF and PZA for LTBI (5.8%) 4–6. Due to the lower hepatic toxicity of RIF alone, rather than that of PZA, the question of the toxicity of PZA and its' acceptability in a prophylactic treatment has been raised 7, 8. To date, information as to the toxicity of PZA in combination with either EMB or a fluoroquinolone is scarce 9–11.

This case series describes the high prevalence of drug-induced hepatitis associated with treatment of latent MDR-TB infection by PZA and EMB in adults.


   PATIENTS AND METHODS
TOP
 ABSTRACT
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Contact-tracing procedures performed for two cases of MDR-TB treated in Geneva University Hospital (Switzerland) during 2003 led to the identification of 18 subjects considered at risk for LTBI. The first index case was a young HIV-positive female from Angola, Africa, with cavitary pulmonary TB. The second index case was a young HIV-negative female from Eritrea (Africa) with multiple pulmonary cavitary lesions. Both cases had a productive cough, and positive sputum smears showing numerous acid-fast bacilli and were consequently strongly infectious.

In total, 12 out of the 18 contacts identified were followed in Geneva University Hospital, while six left the Geneva area and were lost to follow-up. All contacts originated from either sub-Saharan Africa (n = 9) or Eritrea (n = 3). All contacts identified had a tuberculin skin test (TST) induration >10 mm (17±4 mm; TST 2 units of RT 23® Tuberculin; Statens Serum Institut, Copenhagen, Denmark), and definite close contact with either of the two index cases. None of the contacts were aware of a previous TST.

On the basis of the joint American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC) guidelines for treatment of LTBI in contacts exposed to MDR-TB cases, a combined treatment of PZA and EMB was initiated for 9 months 2. Intended doses were 20–25 mg·kg–1·day–1 and 15–20 mg·kg–1·day–1 for PZA and EMB, respectively. This choice was in agreement with susceptibility testing of Mycobacterium tuberculosis strains of index cases. All treatments were initiated between September 2003 and March 2004. Cases were announced to the Swiss national registry of pharmacovigilance.

Liver function testing (ASAT: aspartate aminotransferase; and ALAT: alanine aminotransferase) was performed before the beginning of the chemoprophylaxis, after 2 weeks and then on a monthly basis.

Treatment was discontinued if increase in ALAT or ASAT was greater than four times the upper limit of normal (ALAT: 42 U·L–1; ASAT: 42 U·L–1), or if the patient presented drug-related adverse effects.

Systematic serology for viral hepatitis was not performed, since initial ASAT and ALAT were within normal values in all subjects.


   RESULTS
TOP
 ABSTRACT
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Details of the clinical and laboratory follow-up are summarised in table 1Go. Median age of contacts was 38 yrs (range 31–48 yrs). All had baseline values of ALAT and ASAT within the normal range. None had any comorbidity or medication, albeit for one patient with chronic (undiagnosed) hepatitis B infection and systemic hypertension, treated by diltiazem, hydrochlorothiazide and valsartan. Daily doses of PZA and EMB were mean±SD (range): 23±4 mg·kg–1 (17–33) and 17±3 mg·kg–1 (13–22), respectively.


View this table:
[in this window]
[in a new window]
  		Table. 1— Characteristics, symptoms and liver tests of contacts treated by pyrazinamide(PZA) and ethambutol (EMB) for latent tuberculosis infection

 
Only five out of the 12 (42%) contacts completed their treatment. Six contacts (50%) discontinued because of an increase in ALAT or ASAT above the threshold of four times the upper normal value after 152±69 days (median: 119 days; table 1Go) and two of these cases had gastrointestinal (GI) symptoms. One patient had a mild elevation of liver enzymes associated with GI symptoms requiring discontinuation of medication. No other side-effects were reported, albeit for unspecific visual disturbances in one case with normal visual evoked potentials.

Among the six patients with liver toxicity, peak values ranged from 82–1,338 U·L–1 for ALAT and 164–2,030 U·L–1 for ASAT. For all contacts, liver enzyme values returned to normal after discontinuation of medication.


   DISCUSSION
TOP
 ABSTRACT
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this case series, combined treatment with PZA and EMB for LTBI after exposure to MDR-TB was associated with a remarkably high rate of drug-induced hepatitis (50%; occurring after a median of 4 months of treatment), and, to a lesser extent, GI symptoms, leading to discontinuation of treatment in a total of 58% of contacts treated. ASAT and ALAT levels returned to normal after PZA and EMB were discontinued. No other adverse effects (such as arthralgias or cutaneous reaction) were noted in this study.

As previously mentioned, current USA guidelines recommend the use of PZA with either EMB or a fluoroquinolone as first-line treatment for adults with LTBI related to MDR-TB, for 6–12 months 2. The present report is, to the current authors' knowledge, the first to describe a high rate of drug-induced hepatitis in contacts treated in this context with a combination of PZA and EMB. Previous publications have described high rates of drug-induced hepatitis in contacts treated by PZA with either levofloxacin (47%) or ofloxacin (25–41%) 9–11. Median time to peak increase in ASAT and/or ASAT was approximately 4 weeks in these three studies, with a wide variability (drug-induced hepatitis occurring up to 25 weeks after beginning of treatment). Liver tests returned to normal within 3–5 weeks after discontinuing treatment 10.

EMB is not considered as incriminated in drug-induced hepatitis, and, thus, liver toxicity in this series is most probably exclusively PZA related 7, 8. However, the rate of drug-induced hepatitis in standard treatment for active TB (INH, RIF, PZA and EMB) is ~3% 7. Thus, rates described for combinations of PZA and either RIF (8–9%) 4–6, fluoroquinolones (25–47%) 9–11, or EMB are surprising and yet unexplained. In the present report, treatment was interrupted after a median period of 4 months, thus, prolonged treatment with PZA when compared with the 2 months of standard treatment for active TB may contribute to the increased incidence of liver toxicity. However, drug-induced hepatitis occurred earlier in cases treated with PZA and a fluoroquinolone. Risk factors for PZA-induced hepatitis have been identified in patients undergoing treatment for active TB, such as sex (female), older age (≥60 yrs of age), birth in Asia and HIV infection 7, 12. However, none of these risk factors were relevant in the present study.

Two additional comments must be made as to the results presented. First, all contacts treated for LTBI underwent monthly monitoring of ASAT and ALAT. This is not recommended as a routine measure in treatment for active TB or LTBI 2, 13. The relevance of a mild asymptomatic increase in ASAT and ALAT may, thus, be questioned, and could be overestimated in the data presented. However, documenting ASAT or ALAT levels three times or more above the upper limit of normal level (if symptoms present) or five times above (if asymptomatic) is considered as a mandatory reason for interrupting all potentially hepatotoxic tuberculostatic drugs in ATS/CDC guidelines 13. Thus, the attitude adopted is in agreement with recent recommendations and previous publications 7, 12. Secondly, all contacts were of African origin, most of them from sub-Saharan Africa. The unexpectedly high rate of drug-induced hepatitis could, thus, be related to the ethnic background of the subjects studied. However, to the present authors' knowledge there is no support for this hypothesis in the previous publications relative to treatment for either active TB or LTBI.

Although any conclusion based on available evidence is preliminary, the frequency of drug-induced hepatitis in published reports of patients exposed to MDR-TB, and treated for LTBI with PZA and either EMB or fluoroquinolones, is preoccupying. Drug-induced hepatitis can occur several months after the beginning of treatment. Furthermore, marked increases in ASAT and/or ALAT can be virtually asymptomatic. Systematic monthly monitoring of patients and their liver enzymes is mandatory in this setting.

Furthermore, alternative regimens to those presently recommended must be envisaged and studied, because of the increasing frequency of multidrug-resistant tuberculosis and, thus, the increasing need for an effective treatment for latent tuberculosis infection in these cases.


   REFERENCES
TOP
 ABSTRACT
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. La tuberculose en Suisse en 1999 et 2000. [Tuberculosis in Switzerland in 1999 and 2000]. Bulletin OFSP 2002;9:168–174.
  2. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49:1–51.[Medline] [Order article via Infotrieve]
  3. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey. Chest 1994;106:431–434.[Abstract/Free Full Text]
  4. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003;167:824–827.[Abstract/Free Full Text]
  5. Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med 2003;167:809–810.[Free Full Text]
  6. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640–647.[Abstract/Free Full Text]
  7. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472–1477.[Abstract/Free Full Text]
  8. Sharma SK. Antituberculosis drugs and hepatotoxicity. Infect Genet Evol 2004;4:167–170.[CrossRef][Medline] [Order article via Infotrieve]
  9. Horn DL, Hewlett D Jr, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330:1241[Free Full Text]
  10. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264–1265.[Web of Science][Medline] [Order article via Infotrieve]
  11. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002;167:131–136.[Abstract/Free Full Text]
  12. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026–2030.[Abstract]
  13. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.[Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
K. C. Chang, C. C. Leung, W. W. Yew, T. Y. Lau, and C. M. Tam
Hepatotoxicity of Pyrazinamide: Cohort and Case-Control Analyses
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1391 - 1396.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al.
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy.
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Younossian, A. B.
Right arrow Articles by Janssens, J-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Younossian, A. B.
Right arrow Articles by Janssens, J-P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS